SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing massive trading volume and a significant surge as investors react to a de-risking FDA update for its ANKTIVA bladder cancer application, which importantly does not require new clinical trials. This news, coupled with recent international approvals and high short interest, has ignited widespread community discussion about a potential short and gamma squeeze. The intense momentum highlights a fervent belief in the drug's long-term potential as a cancer treatment, driving bullish sentiment against a backdrop of active short positions.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is currently trending due to its recent award of a prime contract position on the U.S. Missile Defense Agency's SHIELD program, significantly bolstering its standing in government AI data training. The community is highly bullish on this development, anticipating a major breakout, potential short squeeze, and further expansion into defense and sovereign AI markets, with many viewing the company as undervalued.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to compelling positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, showcasing strong efficacy in treatment-resistant patients and a favorable safety profile. The community is buzzing about its "best-in-class" potential in a massive market and a possible short squeeze, with many anticipating significant upside or a partnership. Despite the early stage of development, the innovative mechanism is driving substantial investor conversation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to heightened global market uncertainty, fueled by renewed tariff threats against European nations and the ongoing Greenland situation. The community is sharply divided, with some anticipating a familiar "buy the dip" opportunity for the tech-heavy index, while others fear a more sustained market correction if trade tensions further escalate.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a significant licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as crucial validation for its non-mRNA technology. This development is intensifying community discussions about the stock's high short interest and potential for a squeeze, alongside ongoing pressure from an activist investor for management to expedite further partnerships and unlock core asset value.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is capturing significant attention following multiple analyst upgrades and reports of a substantial U.S. defense contract under the SHIELD program, fueling strong bullish sentiment. The community is actively discussing the stock's ability to maintain its upward momentum against price resistance ahead of its highly anticipated earnings report, with many expecting positive developments from its server CPU demand and foundry initiatives.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively discussed following its announcement of a record date for a digital token initiative, with many anticipating a short squeeze and other upcoming catalysts. This drives significant polarization, as some investors see substantial upside from loyalist support, while others view it as a highly speculative, politically-charged stock susceptible to market volatility and dilution. The stock remains a key talking point, reflecting the strong intersection of media, branding, and political narratives in its trading dynamics.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as regulatory developments create a mixed outlook: a Massachusetts judge issued a preliminary injunction against prediction market Kalshi, a move seen as highly favorable for traditional sportsbooks. This positive catalyst is juxtaposed with the NCAA's call for a federal halt on college sports betting, intensifying investor debate around regulatory impacts and the rising competition from alternative betting platforms. Community sentiment is also weighing recent analyst upgrades and an increased share buyback authorization, leading to notable stock volatility.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group (TWG) is seeing significant conversation following its announced acquisition of a wine trading business valued at $125 million, to be paid in newly issued shares. This strategic expansion into luxury wine has ignited strong community debate, with investors split between concerns over the share dilution at $7.00 per share and those enthusiastically accumulating the stock on the belief of a future rebound. The intense volatility reflects the mixed sentiment surrounding this low-float entity.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing significant momentum, driven by a recent product innovation award and confirmed ongoing work with Celestial AI, now part of Marvell. The community is highly engaged, actively discussing the company's patented Optical Interposer platform as a crucial solution for AI and data center optical interconnects, which many believe positions the stock for a substantial re-rating. Anticipation is building for further announcements and a potential short squeeze as the market increasingly recognizes its technological advantages and strategic partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals Health~Holland Awards Another Innovative Research...

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update PR Newswire STATEN...

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens Acurx Announces Publication in the Nature...

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference Acurx Announces...

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial...

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND, N.Y., Oct...

Are Medical Stocks Lagging  Acurx Pharmaceuticals (ACXP) This Year?

Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Current Price	$2.66
Prev Close	$2.65
Open	$2.59
Dividend Yield	0.00%
50-Day Moving Average	$3.69
Beta	0.86
Avg. Volume	82,527.05
PE Ratio	-0.31

52-Week High	$21.00
52-Week Low	$2.44
Market Capitalization	$6.22M
EPS (Annual)	-$17.45
Price to Book	1.31
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ACXP
Acurx Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACXP News

ACXPAcurx Pharmaceuticals Inc